AVAdrian Valadez

Adrian Valadez

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Adrian Valadez has a total of 55 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Development and validation of a cefepime population pharmacokinetic model to guide treatment for patients with hospital-acquired pneumonia requiring renal replacement

    by Adrian Valadez, Emma Harlan, Marc H. Scheetz, Michael N. Neely, Helen K. Donnelly, Richard G. Wunderink, Nathaniel J. Rhodes

    Cefepime is used in critically ill pneumonia patients, but dosing in renal replacement therapy (RRT) is complicated by altered renal function, extracorporeal removal, and variability in pulmonary epithelial lining fluid (ELF) exposure. We sought to develop an integrated model linking systemic, extracorporeal, and pulmonary cefepime pharmacokinetics in RRT. Pharmacokinetic (PK) data from critically ill adults receiving cefepime and requiring RRT were included. In a dedicated continuous RRT (CRRT) cohort ( n = 8), pre- and post-filter plasma and effluent PK data were collected. Additional patients ( n = 43) requiring RRT also contributed plasma and ELF samples. A non-parametric population PK model was developed using an 80/20 subject-level development-validation split. Covariate models assessed the impact of residual renal function, effluent flow rate, body size, and fixed intradialytic hemodialysis (HD) clearance. Monte Carlo simulations evaluated plasma and ELF target attainment across dosing strategies, weight strata, and minimum inhibitory concentrations (MICs). The final model jointly described systemic, extracorporeal, and pulmonary cefepime disposition using piecewise central volume, native clearance, linear effluent-flow-dependent CRRT clearance, fixed HD clearance, and ELF distribution. Simulations showed adequate plasma target attainment, whereas ELF attainment was sensitive to MIC, target, regimen, and body weight. Continuous infusions of 4 g/day provided adequate ELF attainment at MICs ≤4 mg/L. Plasma-based cefepime target attainment may overestimate pulmonary exposure during RRT, particularly at higher MICs, body weights, and f T>MIC targets. External validation and prospective studies are needed to refine pulmonary target estimates and determine whether plasma-guided Bayesian dosing can reliably ensure site-of-infection exposure.

  • Open Access

    Predictive accuracy of population meropenem models in critically ill pneumonia patients

    by Adrian Valadez, Emma Harlan, Colin Jeantet, Marc H. Scheetz, Michael N. Neely, Helen K. Donnelly, Richard G. Wunderink, Nathaniel J. Rhodes

    Population pharmacokinetic (PK) models may not generalize across critically ill populations. We evaluated the transportability of published parametric and nonparametric meropenem models as Bayesian priors. Seven published meropenem models were implemented in Monolix 2024R1. Nonparametric models were converted to log-normal priors from reported medians and CV%. An independent cohort was used for evaluation. A priori and a posteriori predictions were summarized across eligible observations and separately for observations obtained during continuous renal replacement therapy (CRRT) and in the absence of CRRT. Predictive performance was assessed using relative mean prediction error (rMPE) and relative median absolute prediction error (rMdAPE). An rMPE within ±20% and an rMdAPE ≤30% were defined as acceptable. Seventeen patients, including six receiving CRRT, contributed 74 plasma concentrations. In the pooled cohort, only the Rohani and Shekar models met predefined performance thresholds at both population and individual levels ( a priori rMdAPE 24.6%–26.4%; a posteriori rMdAPE 6.7%–11.1%). In CRRT patients, no model achieved acceptable a priori performance; after Bayesian updating, all CRRT-specified models met accuracy and precision criteria, with the nonparametric models (Reed and Rohani) demonstrating low imprecision. In non-CRRT patients, several models showed population-level bias, but all met predefined accuracy and precision thresholds after Bayesian updating. Among evaluated models, Rohani, Reed, and Shekar demonstrated the most consistent predictive performance across the CRRT and non-CRRT subgroups. Nonparametric model summaries can be translated into parametric priors, but model selection remains critical when applying Bayesian dosing in critically ill patients.


  • Defining Optimal Sampling Strategies for Cefepime Model-Informed Precision Dosing

    by Adrian Valadez, Brandon J. Smith, Ryan K. Shields, Samantha Pan, Erin Weslander, Shannon R. Galvin, Jasmine H. Hughes, Maria-Stephanie A. Hughes, Fekade B. Sime, Jason A. Roberts, et al.

    Background: Population pharmacokinetic (PK) models can be combined with Bayesian estimation to optimize dosing regimens. The impact of sample collection time on the accuracy and precision of Bayesian predictions was evaluated. Methods: Data from adult and pediatric patients were used to develop a cefepime population PK model for Bayesian prior use. Holdout data were used for model evaluation. Clinical dosing regimens in the latter cohort were used to conduct optimal sample-time analysis. The accuracy and precision of the Bayesian predictions were assessed as a function of infusion duration and the differences between the observed and optimal sampling times. Analyses were conducted using Pmetrics for R. Results: An allometrically scaled 2-compartment model was fitted (n = 71 patients, 685 observations). In the holdout group (n = 116 patients, 203 observations), the posterior Bayesian fit was acceptable ( R 2 = 0.923; relative bias −3%; median absolute error, 11.2%; F20, 72%; and F30, 86%). Mid-interval sampling was the optimal 1-sample design for 11/16 regimens. In the 2-sample design, a peak (8/16 regimens) and trough (9/16 regimens) approach was frequently optimal. The 2-sample design yields a lower Bayesian risk of misclassification. For 0.5-hour infusions, Bayesian predictions were similarly accurate but significantly more imprecise when samples were collected >2 hour away from the optimal time versus within ±1 hour of the optimal time (ΔRMSE: 8.98 mg/L, 95% CI: 3.61–15.7 mg/L). For 3 hours infusions, no significant differences in the accuracy or imprecision of the Bayesian predictions were noted. Conclusions: The nonparametric cefepime population PK model fit as a Bayesian prior in the holdout group. The optimal timing of PK sample collection varied according to regimen type and infusion duration. The precision of Bayesian estimates was lower for 0.5-hour infusions when samples were collected further from the model-predicted regimen-specific optimal collection times.

  • Bayesian Dosing Simulator ( BDS ): A Pharmacokinetic Modeling Tool for Optimized Antibiotic Therapy

    by Adrian Valadez, Marc H. Scheetz, Michael N. Neely, Helen K. Donnelly, Erin Korth, Richard G. Wunderink, Nathaniel J. Rhodes

    Background: Meropenem is widely used to treat hospital‐acquired pneumonia in critically ill patients, with efficacy dependent on the time that free concentrations exceed the minimum inhibitory concentration ( f T > MIC). In practice, single‐sample therapeutic drug monitoring (TDM) may not ensure target attainment, particularly in patients requiring continuous renal replacement (CRRT). Model‐informed precision dosing (MIPD) enables individualized, real‐time adjustments, but implementation is limited. Herein, we developed a Shiny application for Bayesian meropenem dose optimization. Methods: A previously published nonparametric model was translated into a parametric Bayesian framework with maximum a posteriori (MAP) updating implemented through a Shiny interface. Plasma pharmacokinetic (PK) data from critically ill patients served for external validation. Posterior predictions were benchmarked against population and individual (MAP) outputs from Pmetrics 3.09 and population median profiles from 1000 Monte Carlo simulations per patient. Predictive performance was assessed using relative median prediction error ( r MPE) and relative median absolute prediction error ( r MAPE), for the combined cohort overall and stratified by CRRT status. Sparse sampling scenarios (one, two, and three observations per patient) were also evaluated. Results: Eighteen patients were evaluated (non‐CRRT n = 13; CRRT n = 5). In Pmetrics, r MPE ranged from −7.7% to 9.4% and r MAPE from 18.5% to 25.5% across renal replacement strata and prediction types. Simulation‐based population predictions yielded greater error, with r MPE/ r MAPE of −25%/34% in CRRT patients and −21%/30% in non‐CRRT patients. Across Bayesian Dosing Simulator (BDS) sampling scenarios, prediction error remained within prespecified limits ( r MPE ±20%, r MAPE ≤ 30%), with F20 ranging from 80% to 94% and F30 from 87% to 94%. Conclusion: A validated nonparametric meropenem model was successfully implemented within an open‐source Bayesian framework yielding predictive accuracy comparable to the reference model with robust performance under sparse sampling, supporting its feasibility for individualized meropenem dosing. Prospective evaluation of its clinical safety and effectiveness is needed.


  • Open Access

    Critical threshold target attainment rates for tazobactam combined with piperacillin among patients admitted to the ICU with hospital-acquired pneumonia

    by Ryan Williamson, Marta Zurawska, Adrian Valadez, Emma Harlan, Marc H. Scheetz, Michael N. Neely, Paul R. Yarnold, Mengjia Kang, Helen K. Donnelly, Franciso Martinez, et al.

    Optimizing antibiotic exposures in hospital-acquired pneumonia (HAP) is crucial; however, dosing decisions often overlook target levels for the beta-lactamase inhibitor tazobactam (TAZ), and the impact of renal dysfunction and renal replacement therapy on TAZ pharmacokinetics (PK) remains poorly described. We developed a population PK model of TAZ using 162 plasma samples from 35 ICU patients with HAP, including those receiving continuous renal replacement therapy (CRRT). TAZ concentrations were quantified using validated LC-MS/MS methods. A one-compartment model was fit using Monolix, with clearance modeled as a function of creatinine clearance, CRRT effluent flow rate, and intermittent hemodialysis. Monte Carlo simulations assessed the probability of unbound TAZ concentrations exceeding 1, 2, or 4 mg/L for 100% of the interval between 24 and 48 h across intermittent, extended, and continuous infusion (CI) regimens, stratified by renal function and CRRT. TAZ clearance was driven by renal function and CRRT flow rate. All regimens achieved ≥90% probability of target attainment (PTA) at thresholds of 1–2 mg/L. At 4 mg/L, PTA fell below 90% in patients with creatinine clearance ≥150 mL/min for all regimens, with low-dose CI performing the worst. High-dose CI improved PTA at this higher threshold but may increase the risk of piperacillin overexposure. TAZ exposures sufficient for enzymatic beta-lactamase inhibition are generally achieved with standard dosing for lower thresholds but not for more aggressive targets (e.g., high extended-spectrum β-lactamase expression), particularly in patients with preserved or augmented renal function, who may require therapeutic drug monitoring or alternative therapy.


  • Open Access

    Pharmacokinetic-pharmacodynamic target attainment with continuous infusion piperacillin in patients admitted to the ICU with hospital-acquired pneumonia

    by Marta Zurawska, Adrian Valadez, Emma Harlan, Ryan Williamson, Marc H. Scheetz, Michael N. Neely, Paul R. Yarnold, Mengjia Kang, Helen K. Donnelly, Franciso Martinez, et al.

    Optimizing β-lactam antibiotic exposure in critically ill patients with hospital-acquired pneumonia (HAP) remains a challenge due to significant pharmacokinetic variability, particularly in the setting of renal dysfunction and replacement therapies. Continuous infusion (CI) of piperacillin/tazobactam aims to improve pharmacodynamic target attainment, though both subtherapeutic and potentially toxic concentrations have been reported in practice. We developed a population pharmacokinetic model of piperacillin using 162 plasma samples from 35 intensive care unit (ICU) patients with HAP, including those receiving continuous renal replacement therapy (CRRT). Piperacillin concentrations were quantified using a validated LC-MS method. A one-compartment model parameterized with renal and non-renal clearance was implemented in Monolix, incorporating creatinine clearance (CrCL), CRRT effluent flow rate, and intermittent hemodialysis as key covariates. Monte Carlo simulations in Simulx evaluated steady-state drug exposures following renal dose-adjusted CI regimens. Simulation showed that renally adjusted lower doses administered via CI (3–9 g/day) achieved target concentrations in 74–82% of patients with CrCL ≤75 mL/min. Higher doses (6–12 g/day) resulted in >20% of patients exceeding 96 mg/L across all renal strata. Among CRRT patients, lower doses provided a 100% probability of maintaining targeted piperacillin concentrations. In patients with supra-normal renal function (i.e., CrCL = 150 mL/min), low-dose CI regimens yielded a 6.1% probability of underexposure, compared to 2.7% with high-dose. CI PIP dosing based on CrCL results in variable exposures among ICU patients. Individualized dosing of PIP may be required to optimize efficacy and minimize toxicity in ICU patients treated with CI dosing.


  • Open Access

    Individual target pharmacokinetic/pharmacodynamic attainment rates among cefepime-treated patients admitted to the ICU with hospital-acquired pneumonia with and without ECMO

    by Adrian Valadez, Marta Zurawska, Emma Harlan, Marc H. Scheetz, Michael N. Neely, Paul R. Yarnold, Mengjia Kang, Erin Korth, Francisco Martinez, Bridget Giblin, et al.

    Cefepime (FEP) is used for hospital- and ventilator-associated pneumonia when Pseudomonas aeruginosa is involved. However, its pharmacokinetics (PK) in severe pneumonia necessitating extracorporeal membrane oxygenation (ECMO) remain unclear. This single-center, prospective study enrolled 70 mechanically ventilated patients with suspected pneumonia ( n = 9 on ECMO), excluding those on renal replacement therapy. Dosing followed institutional renal function-based protocols. Plasma concentrations were quantified by liquid chromatography-tandem mass spectrometry, and a two-compartment PK model was developed using Pmetrics for R, with volume of distribution (Vd) scaled to body weight and ECMO status, and clearance (CL) scaled to renal function. Target attainment was calculated from Bayesian posterior predictions, and Monte Carlo simulations evaluated the cumulative fraction of response (CFR) for regimens of 2 g IV every 8 h, administered as either 0.5 h intermittent or 4 h extended infusion with or without a 2 or 3 g loading dose (LD) (0.5 h). Success was defined as achieving 100% f T >1xMIC within 24 h for 80% of isolates. Seventy patients (60% male, n = 9 ECMO) contributed 114 plasma samples (1–14 per patient). The model fit the data well. ECMO was associated with a 2.8-fold increase in Vd without altering CL. Monte Carlo simulations demonstrated that standard dosing without an LD failed to achieve CFR ≥ 80% in ECMO patients. Incorporating a 3 g but not 2 g LD restored CFR to ≥80% in ECMO. ECMO significantly increased FEP Vd in intensive care unit patients, suggesting sub-optimal target attainment at higher minimum inhibitory concentrations. A 3 g LD appears essential for target attainment, underscoring the need for revised dosing strategies in ECMO.


  • Open Access

    Population pharmacokinetics of meropenem-vaborbactam in acutely ill hospitalized patients with various degrees of renal dysfunction including continuous renal replacement therapy

    by Griffin Reed, Adrian Valadez, Brandon J. Smith, Erin K. McCreary, Ellen G. Kline, Michael N. Neely, Kevin M. Squires, Ryan K. Shields, Nathaniel J. Rhodes

    Real-world meropenem-vaborbactam (MVB) pharmacokinetic-pharmacodynamic (PK/PD) attainment data in patients with renal dysfunction including continuous renal replacement (CRRT) are lacking. We evaluated MVB PK in patients with renal dysfunction and CRRT. Patients requiring hemodialysis were excluded. Plasma concentrations were quantified using LC-MS/MS. Multiple compartmental PK models and covariate effects were evaluated using Pmetrics 2.1.1. Free (f) fractions of 98% and 67% were assumed with targets of 40%– 100% f T >MIC and f AUC/MIC >38 for meropenem (MEM) and vaborbactam (VAB), respectively. Individual patient PK/PD attainment was evaluated using Bayesian posterior predictions. Probability of target attainment (PTA) stratified by MIC and cumulative fraction of response (CFR) vs the EUCAST K. pneumoniae distribution were evaluated for 2 and 4 g MVB regimens. Eighteen patients (54% female, 17% CRRT) aged 54 ± 14 years, weighing 91 ± 31 kg with a CrCL of 114 ± 102 mL/min/1.73 m 2 at baseline, contributed 83 plasma samples. For each drug, a one-compartment PK model was identified. Non-CRRT and residual clearance of MEM was higher than VAB, resulting in VAB accumulation. Individual-patient target attainment was variable. MEM PTA was >90% at MICs up to 0.5 mg/L, and VAB PTA was >90% at MICs up to 4 mg/L across renal states. CFR for MEM was >80%, and CFR for VAB was >70% in patients with renal dysfunction or CRRT and standard PK/PD targets with renal dosing regimens. For infections with MICs up to 1 mg/L, MVB regimens of 2 g IV every 8 h were adequate in CRRT. Studies linking MVB attainment to clinical outcomes are needed.


  • Intra-operative redosing of cefepime in massive blood loss: population vs individualized approaches

    by Krista Paplaczyk, Erin Weslander, Adrian Valadez, Chitaru Kurihara, Shannon R. Galvin, Kyle Leonida, Griffin Reed, Nathaniel J. Rhodes